Characterization of bone marrow lymphoid infiltrates after immunochemotherapy for follicular lymphoma

American Journal of Clinical Pathology

Volumn 128, Issue 6, 2007, Pages 974-980

  Laurent, Camille ^a   De Paiva, Geisilene Russano ^a   Ysebaert, Loic ^b   Laurent, Guy ^b   March, Michel ^a   Delsol, Georges ^a   Brousset, Pierre ^a,b  

^a France   (France)

^b CHU PURPAN   (France)

Author keywords

Follicular lymphoma; Nonmalignant immature B cells; Rituximab; T regulator and mast cell infiltrates

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD79A ANTIGEN; CYCLOPHOSPHAMIDE; DNA NUCLEOTIDYLEXOTRANSFERASE; DOXORUBICIN; PREDNISONE; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; COP PROTOCOL 2; MONOCLONAL ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B LYMPHOCYTE; BONE MARROW; CANCER CHEMOTHERAPY; CELL LINEAGE; CELL MATURATION; CELL POPULATION; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; LYMPHOID CELL; LYMPHOMA CELL; MALE; MAST CELL; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; AGED; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE SUBPOPULATION; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REMISSION; RETROSPECTIVE STUDY; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOSUPPRESSION; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PREDNISONE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 38049053490     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/LREBX069UXDYMBXV     Document Type: Article

References (21)

1. Nathwani BN, Harris NL, Weisenburger D, et al. Follicular lymphoma. In: Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:162-167.
2. Tsujimoto Y, Cossman J, Jaffe E, et al. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228:1440-1443.
3. Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226:1097-1099.
4. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-1423.
5. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725-3732.
6. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295-3301.
7. Coiffier B. Monoclonal antibody as therapy for malignant lymphomas. C R Biol. 2006;329:241-254.
8. Arber DA, George TI. Bone marrow biopsy involvement by non-Hodgkin's lymphoma: frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens. Am J Surg Pathol. 2005;29:1549-1557.
9. Torlakovic E, Torlakovic G, Brunning RD. Follicular pattern of bone marrow involvement bv follicular lymphoma. Am J Clin Pathol. 2002;118:780-786.
10. Douglas VK, Gordon LI, Goolsby CL, et al. Lymphoid aggregates in bone marrow mimic residual lymphoma after rituximab therapy for non-Hodgkin lymphoma. Am J Clin Pathol. 1999;112:844-853.
11. Schroder C, Azimzadeh AM, Wu G, et al. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol. 2003;12:19-28.
12. Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positivc regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108:2957-2964.
13. Alvaro T, Lejeune M, Salvado MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol. 2006;24:5350-5357.
14. Lee AM, Clear AJ, Calaminici M, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol. 2006;24:5052-5059.
15. Sfikakis PP, Souliotis VL, Fragiadaki KG, et al. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol. 2007;123:66-73.
16. Cheson BD, Horning SJ, Coiffier B, et al, for the NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244-1253.
17. Matsumoto Y, Nomura K, Matsumoto S, et al. Detection of t(14;18) in follicular lymphoma by dual-color fluorescence in situ hybridization on paraffin-embedded tissue sections. Cancer Genet Cytogenet. 2004;150:22-26.
18. Rambaldi A, Lazzari M, Manzoni C, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood. 2002;99:856-862.
19. Lu LF, Lind EF, Gondek DC, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature. 2006;442:997-1002.
20. Wolf E, Harms H, Winkler J, et al. Terminal deoxynucleotidyl transferase-positive cells in trephine biopsies following bone marrow or peripheral stem cell transplantation reflect vigorous B-cell generation. Histopathology. 2005;46:442-450.
21. McKenna RW, Washington LT, Aquino DB, et al. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood. 2001;98:2498-2507.